CDK4 and breast carcinoma: The ongoing Endocrine Optimization Pilot of the I-SPY2 Trial enrolls patients with clinical stage II-III breast cancer with low predicted response to chemotherapy based on genomic assay and randomizes to novel endocrine therapy-based agents with or without CDK4/6 inhibitors in the neoadjuvant setting.